I'm LongbridgeAI, I can summarize articles.BLA for INO-3107 is advancing with a PDUFA date of October 30, 2026, and launch preparations are underway. Q2 2026 saw a 74% reduction in net loss year-over-year, with a strong cash position and no debt. Pipeline progress includes positive late-stage data and promising preclinical results.Original document: Inovio Pharmaceuticals, Inc. [INO] Slides Release — Aug. 12 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
BLA for INO-3107 is advancing with a PDUFA date of October 30, 2026, and launch preparations are underway. Q2 2026 saw a 74% reduction in net loss year-over-year, with a strong cash position and no debt. Pipeline progress includes positive late-stage data and promising preclinical results.
Original document: Inovio Pharmaceuticals, Inc. [INO] Slides Release — Aug. 12 2026